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Background: We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to
14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/
52/58) vaccine types, by region
Methods: Women ages 15–26 and 24–45 years from 5 regions were enrolled in qHPV vaccine clinical
trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS)
cases were diagnosed by pathology panel consensus.
Results: Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/
31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in
9vHPV type prevalence in CIN1 (50%) and CIN2/3 (81–85%). Types 31/33/45/52/58 accounted for 25–
30% of CIN1 in Latin America and Europe, but 14–18% in North America and Asia. Types 31/33/45/52/58
accounted for 33–38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17–18% of
CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 hadB.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
nd NCT00090220.
ch Program (CERP). Institut
ospitalet de Llobregat, 08908
Castellsagué).
X. Castellsagué et al. / Papillomavirus Research 2 (2016) 61–6962similar or higher prevalence than qHPV types in CIN1 and were attributed to 2–11% of CIN2/3.
Conclusions: The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geo-
graphic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some
CIN1, and to a lesser extent CIN2/3.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A 9-valent HPV (9vHPV) vaccine was licensed in 2014 in the
United States and in 2015 in Canada, the European Union and
Australia for the prevention of cervical, vulvar, vaginal, and anal
cancers, their respective pre-cancerous lesions, and genital warts
caused by HPV types 6/11/16/18/31/33/45/52/58 in females and
males aged 9–26 years. The vaccine was developed to protect
against cancer and precancer beyond what is already provided by
the current quadrivalent vaccine (qHPV vaccine), which targets the
high risk (HR) (i.e., cancerous) HPV types 16/18. The 9vHPV vac-
cine additionally targets the 5 next most common HPV types
found in cervical cancer worldwide (HPV 31/33/45/52/58). Both
the 9vHPV and qHPV vaccines also protect against the low risk
(i.e., not likely to cause cancer) types 6/11 responsible for 90% of
genital warts cases.
In a pivotal Phase III efﬁcacy study, the 9vHPV vaccine pre-
vented approximately 97% of cervical, vaginal and vulvar pre-
cancers caused by HPV 31/33/45/52/58. The vaccine also generated
antibody responses to HPV6/11/16/18 that were non-inferior to
those generated by the qHPV vaccine and had a favorable safety
proﬁle [1].
Approximately 90% of cervical cancers worldwide are attrib-
uted to infection with the 7 HR HPV types targeted by the 9vHPV
vaccine (i.e., HPV16/18/31/33/45/52/58) [2,3]. A previous study of
women in Brazil, Mexico, India and China also found that
approximately 90% of cervical cancer cases in these countries are
attributed to the 9vHPV types, with some minor regional variation
in the proportion of these cancers attributed to HPV 31/33/45/52/
58 (12–19% variability) [7]. Similarly, a previous study using qHPV
clinical trial data found that approximately 85% or more of cervical
intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma
in situ (AIS), and approximately 50% of CIN1 lesions are attributed
worldwide to the types targeted by the 9vHPV vaccine [4]. How-
ever, regional data on the proportion of CIN and AIS attributed to
the 9vHPV vaccine types are sparse. Such data are essential for
estimating the regional impact of HPV vaccines on the rates of
cervical lesions. For example, the greatest impact of HPV vacci-
nation is expected in low- and middle-income countries where the
current qHPV and bivalent HPV vaccines targeting HPV16/18 are
estimated to potentially reduce cancer risk by 40–50% at 70%
vaccine uptake and where well organized screening programs are
lacking [5–7].
Using data from the qHPV vaccine clinical trials, we estimated
the proportion of CIN1-3 in North America, Latin America, Europe,
Asia, and Oceania [8–11] attributed to the 14 HPV types tested in
the trials (HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59), as well
as the proportion attributed overall to the 9vHPVvaccine types (6/
11/16/18/31/33/45/52/58) and by the 9vHPV vaccine's constituent
qHPV types (6/11/16/18) and 5 new types (31/33/45/52/58).2. Materials and methods
2.1. Objective
The objective of this analysis was to determine the proportion
of low and high grade cervical lesions (CIN1-3) attributed to the9vHPV vaccine types (6/11/16/18/31/33/45/52/58), to the qHPV
types (6/11/16/18), to the 5 new types targeted by the 9vHPV
vaccine (31/33/45/52/58), as well as to 5 other measured non-
vaccine HR HPV types (35/39/51/56/59), across the 5 regions
studied.
2.2. Study designs and population
Data from 3 randomized double-blind, placebo-controlled
clinical trials of the qHPV vaccine were used in this analysis.
Protocols 013 and 015 included 17,622 women (8798 in placebo
group) 15–26 years old from 23 countries enrolled between
December 2001 and May 2003, while Protocol 019 included 3819
women (1908 in placebo group) 24–45 years old from 7 countries
enrolled between June 2004 and April 2005. Participants in the
trials were followed for approximately 4 years. As Protocols 013
and 015 enrolled only a small percentage of women above the age
of 23, the age range for Protocol 019 was chosen to overlap with
these studies. The proportions of subjects enrolled from the fol-
lowing regions for the younger and older age groups, respectively,
are: North America (13%, 14%), Latin America (32%, 42%), Europe
(51%; 13%), Asia (2%; 31%) and Oceania (2%, only included for
women aged 15–26 years). Further details of subjects and patients
with lesions and the countries included in these trials are provided
in Supplementary Appendix Table A.1
The study designs, protocols, and results of the primary
hypotheses for each of the studies have been previously described
[8–10]. The studies were conducted in accordance with principles
of Good Clinical Practice and were approved by the appropriate
institutional review boards and regulatory agencies.
2.3. Analyses for infection
HPV anogenital infection prevalence was reported as one
potential measure of HPV types circulating in the study popula-
tion, and it can be compared to HPV types responsible for causing
low and high grade cervical lesions. An endo/ectocervical swab
(one specimen) and a combined labial/vulvar/perianal swab were
obtained from all subjects across the trials. Prevalence of HPV
infection at day 1 was assessed in the vaccine and placebo arms
combined to increase precision (given the randomized nature of
the trials, it is expected that the placebo arm infection prevalence
will be similar to the prevalence in the combined trial arms). In
each study, day 1 swabs were tested for 14 HPV types (6/11/16/18/
31/33/35/39/45/51/52/56/58/59) using a PCR-based assay as pre-
viously described [12–14].
2.4. Cervical neoplasia diagnosis
All biopsies and excisional procedure specimens were tested
for the 14 HPV types as previously described [4]. All specimens
were processed and adjacent histological sections of each speci-
men were ﬁrst read for clinical management by pathologists at a
central laboratory (Diagnostic Cytology Laboratories, Indianapolis,
IN) and then read for endpoint determination by a panel of up to
4 pathologists who were blinded to central laboratory and clinical
diagnoses, treatment group, and HPV status. The following
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here: CIN grade 1, 2 and 3, and/or AIS. There were no cases of
cervical cancer.
Over approximately 4 years of follow-up of 10,706 women in
the placebo arms of the 3 trials, 1539 cases of CIN1, 945 cases of
CIN2 or CIN3 (CIN2/3), and 24 cases of AIS were diagnosed. Of
these, most were identiﬁed among the 8798 women aged 15–26,
as follows: 1366 CIN1, 456 CIN2, 393 CIN3, and 19 AIS. The
remaining lesions were diagnosed among the 1908 women aged
24–45 (Table A.1).2.5. Statistics
Analyses of the prevalence of the 14 tested HPV types in cer-
vical lesions (deﬁned as a biopsy or surgical excisional specimen)
was performed in 10,706 women randomized to the placebo arms
of the trials (representing over 99% of the total number rando-
mized to the placebo arms). Because some women developed
more than one lesion during the studies, an individual could be
counted multiple times in the tables and ﬁgures.
We used 4 approaches (described below) to estimate the
attribution of cervical lesions to individual HPV types, with
2 approaches to adjust for lesions with more than one HPV type
detected. In this analysis, to avoid unstable estimates resulting
from small sample sizes, attribution was reported only for regions
with 420 lesions of a given CIN grade (e.g., CIN1). For each of the
4 analyses, all lesions (i.e. both HPV positive and HPV negative)
were included in the denominator, as the HPV negative lesions
might have been caused by a non-tested type.
) Minimum (Min) Estimate: The minimum estimate of attribution
was calculated by including in the numerator only those lesions
in which a respective HPV type was present as a single infection.
) Proportional (Prop) Attribution Estimate: Consistent with the
literature [15,16], this estimate was calculated following the
method of Insinga et al., [17] in which a fractional allocation for
each individual HPV type was used when evaluating lesions
with more than one HPV type detected. This was based on the
relative number of instances in which each HPV type was
observed as a single infection in a lesion of a given grade. For
example, if one were to derive an apportionment for two CIN3
lesions found to test positive for HPV16 and 51, and if there
were nine CIN3 lesions with HPV16 only and a single CIN3
lesion with HPV51 only, then [2*9/(9þ1)] or 1.8 of these
2 multiple infected lesions would be attributed to HPV16 and
[2*1/(9þ1)] or 0.2 attributed to HPV51.
) Hierarchical: A modiﬁed version of the hierarchical attribution
estimate of Wentzensen et al. was also performed for lesions
with more than one HPV type detected [18]. We attributed the
cervical lesion to the HPV type that is most commonly detected
in invasive cervical cancer [19]. For example, a lesion with
HPV16 and 59 would be attributed to HPV16 because HPV16 is
more commonly found in cervical cancer. A lesion was attrib-
uted to HPV 31/33/45/52 or 58 (i.e. the additional high-risk HPV
types included in the 9vHPV vaccine), only if there were no co-
infection with HPV16 and/or 18; and to HPV35/39/51/56/59 (i.e.
the other high-risk HPV types tested which are less commonly
detected in invasive cervical cancers) [19]. only if there were no
co-infection with HPV16/18/31/33/45/52 and/or 58.
) Any type estimate: This estimate was calculated by including in
the numerator any lesion in which a respective HPV type was
present, regardless of co-infection with other types.3. Results
3.1. HPV anogenital infection prevalence on day 1 (placebo and
vaccine arms combined)
The most commonly detected HPV type in young women (aged
15–26) within any given region was generally HPV16, followed by
HPV56 and 51, while in older women (aged 24–45), HPV56
infection was most common, followed by HPV51 and 52 (Table 1,
Fig. 1, Supplementary Appendix Table A.2). However, in Asia,
HPV52 had the highest prevalence in both age groups. Approxi-
mately 10–15% of the younger age group and 10% of the older age
group had more than one HR HPV type (i.e., “coinfections”) mea-
sured at day 1, with the exception of Asia (2–3% coinfections in
both age groups).
Overall, the prevalence of anogenital infection with any of the
14 measured HPV types on day 1 (placebo and vaccine arms
combined) was fairly similar across all regions and both age
groups (28–33%), with the exceptions of Asia, which had a lower
prevalence in both age groups (12–14%), and Latin America, where
the younger cohort had higher prevalence than the older cohort
(38% vs 30%). Irrespective of age, in North America, Europe, and
Oceania, anogenital infection prevalence was similar for any non-
vaccine HPV type (16–20%), any qHPV type (12–16%), and 9vHPV
type (20–25%), while in Latin America and Asia, HPV prevalence
was also similar, though lower than in the other regions: any non-
vaccine type (6%), and qHPV type (3–4%), and any 9vHPV type (7–
8%).
3.2. HPV prevalence in CIN lesions (placebo arms)
Among the high-risk 9vHPV types and non-vaccine types, there
was less than a 5% difference across each region for each of the
proportional, hierarchical, or any attribution estimates. Thus, the
proportionally-weighted results are discussed below, with addi-
tional ﬁndings provided in Supplementary Appendix Figs. A.2 and
A.3.
3.2.1. CIN1 lesions
The most commonly detected HPV types in CIN1 lesions within
any given region were generally similar to the most common types
in HPV anogenital infection (Table 1, Supplementary Appendix
Table A.3). HPV16 was typically the most common, followed by
HPV39, 51, 52, and 56. Across North America, Europe, and Asia,
approximately 30–40% of CIN1 lesions were coinfected in young
women, with approximately twice as many coinfections as in the
older age group: 15% (Asia) and 20% (Europe). In contrast, in Latin
America, the proportion of co-infections in CIN1 lesions was
similar in both the younger and older age groups (21–22%).
The non-vaccine HPV types (35/39/51/56/59) accounted for
approximately 25–30% of CIN1 lesions in Latin America and Eur-
ope in both age groups, and 36% in North America (young women)
(Table 1, Fig. 2, Fig. 3). In Oceania and Asia, where there were
substantially fewer lesions, the 5 non-vaccine types accounted for
47% and 15–19% of CIN1 cases, respectively (Table 1, Fig. 3, Sup-
plementary Appendix Fig. A.3).
In comparison to the qHPV types, in North America, Asia, and
Oceania, the 5 new HPV types addressed by the 9vHPV vaccine
accounted for an additional 18%, 14%, and 11% of CIN1 cases, while
in Latin America and Europe, the 5 new types accounted for a
higher proportion of these lesions (25–28%) (Table 1, Fig. 2, Sup-
plementary Appendix Fig. A.3). HPV6/11 accounted for less than
10% of CIN1 lesions in any region or age group (approximately 4%
of the CIN1 in young women in North America, Europe, and Latin
America; 8% in Asia, and 2% in the older age group in Latin
America).
Table 1
Summary of HPV prevalence (%) in cervical infections and HPV attribution (%) to cervical lesions, by age (15–26 and 24–45 years old), region, and HPV type combinations.
HPV type HPV infection CIN1 adjustedn CIN2/3 adjustedn
15–26 24–45 15–26 24–45 15–26 24–45
North America
Number of lesions – – 162 14 85 3
Most prevalent types 16/51/56 56/16/52 16/39/56 56/16/45 16/31/52 NA
41 HR type 12% 10% 34% NA 28% 0%
Any non-vaccine type 17% 20% 36% NA 7% NA
Any qHPV type 14% 12% 26% NA 63% NA
Any 9vHPV type 20% 21% 44% NA 85% NA
Latin America
Number of lesions – – 549 103 239 37
Most prevalent types 16/56/51 56/52/16 16/56/58 16/58/56 16/58/31 16/52/58
41 HR type 15% 9% 21% 22% 23% 11%
Any non-vaccine type 6% 6% 30% 25% 8% 11%
Any qHPV type 4% 3% 21% 28% 50% 61%
Any 9vHPV type 9% 8% 48% 56% 83% 78%
Europe
Number of lesions – – 606 15 496 14
Most prevalent types 16/56/51 56/16/51 16/51/56 51/31/39 16/31/52 16/31/52
41 HR type 15% 11% 38% 20% 40% 43%
Any non-vaccine type 19% 19% 29% NA 9% NA
Any qHPV type 16% 13% 28% NA 44% NA
Any 9vHPV type 25% 22% 53% NA 82% NA
Asia
Number of lesions – – 21 40 10 42
Most prevalent types 52/16/51 52/51/39 16/39/51 52/16/51 16/52/33 16/52/31
41 HR type 3% 2% 29% 15% 30% 14%
Any non-vaccine type 6% 6% 19% 15% NA 2%
Any qHPV type 4% 3% 43% 22% NA 34%
Any 9vHPV type 9% 8% 57% 38% NA 71%
Oceania
Number of lesions – – 28 – 19 –
Most prevalent types 51/16/56 – 51/16/58 – 31/16/51 –
41 HR type 11% 39% – 42% –
Any non-vaccine type 16% – 47% – NA –
Any qHPV 13% – 28% – NA –
Any 9vHPV 22% – 39% – NA –
NA: not applicable (sample size too small); – population not included in trial;
HR¼ high risk HPV type (total of 12 HR types tested); non-vaccine types: 35/39/51/56/59; qHPV type: 6/11/16/18; 9vHPV types: 6/11/16/18/31/33/45/52/58
n Proportional weighted.
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in North America, Europe and Latin America were attributed to the
9vHPV vaccine types, consistent with the estimate for all regions
combined (Table 1, Fig. 2). In Asia and Oceania, where there were
substantially fewer CIN1 lesions in young women, the 9vHPV
types respectively accounted for 57% and 39% of CIN1. In the older
women in Asia and Latin America, the 9vHPV types respectively
accounted for 38% and 56% of CIN1 lesions (Table 1, Supplemen-
tary Appendix Fig. A.3).
3.2.2. CIN2/3 lesions
Other than HPV16, the next most commonly detected HPV
types in CIN2/3 lesions were generally different than the most
common types in HPV anogenital infection and CIN1 lesions, and
included in the 9vHPV vaccine types (HPV 31, 52, 58) (Table 1,
Supplementary Table A.3).
In all regions, approximately 30–40% of CIN2/3 in young
women were coinfected with other types, with the exception of
Latin America (23%) (Table 1). In the older age groups, a smaller
proportion of CIN2/3 were coinfected (14% Asia, 11% Latin Amer-
ica), while in Europe, approximately 40% of CIN2/3 lesions were
coinfected in both age groups.
There was also minimal regional variation in the prevalence of
the 5 other non-vaccine types in CIN2/3 cases, ranging from 7% to
11%, except for Asia (2%, older women only) (Table 1, Fig. 3). Inboth age groups and all regions, the relative contribution of the
non-vaccine HPV types decreased as lesion severity increased. For
example, in young women, the relative contribution of the 5 non-
vaccine types was 20–36% for CIN1, 8–15% for CIN2, and 2–4%
for CIN3.
In comparison to the qHPV vaccine types, the 5 new vaccine
types generally accounted for approximately 30–40% of CIN2/3 in
both age groups, with the exception of North America and Latin
America (older age group), where the 5 new types accounted for
16–18% of CIN2/3 lesions (Table 1, Fig. 2, Supplementary Appendix
Fig. A.3).
Approximately 80% (78–85%) of CIN2/3 in North America,
Europe and Latin America were attributed to the 9vHVP vaccine
types, whereas in Asia (older women only), 71% of the CIN2/3
lesions were attributed to these types (Table 1, Fig. 2, Supple-
mentary Fig. A.3). It is important to note that by grade, the 9vHPV
vaccine types were attributed to 72–80% of CIN2 but to 90–97% of
CIN3 lesions.
3.2.3. Adenocarcinoma in situ
Very few AIS lesions were detected within any region, and all
but 1 lesion were infected with HPV16. Of the 9 total AIS lesions in
Latin America (both age groups combined), 7 had HPV16 only, one
was co-infected with HPV16/58, and one with HPV16/52. Of the 13
total AIS lesions in Europe, 5 had HPV16/18 only, 6 had HPV16/18
Fig. 1. Prevalence of cervical HPV infection at baseline by region, irrespective of co-infections, vaccine and placebo arms combined. Non¼non-vaccine type (HPV35/39/51/
56/59); qHPV¼quadrivalent vaccine HPV type (HPV6/11/16/18); 9vHPV¼9-valent vaccine HPV type (HPV6/11/16/18/31/33/45/52/58). Total data adapted from reference 4.
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Fig. 2. Percent of CIN1-3 attributed to the respective HPV types in women ages 15–26, by region, proportional method. Total data adapted from reference (4).
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HPV type detected. Of the 2 AIS lesions in Asia (older women
only), both had HPV16 only.4. Discussion
The present study is one of the ﬁrst to assess HPV type-speciﬁc
attribution to CIN by geographical region. With respect to CIN1, the5 new HPV types (31/33/45/51/58) in the 9vHPV vaccine accounted
for approximately 25–30% of lesions in Latin America and Europe,
and 14–18% of lesions in North America and Asia. With respect to
CIN2/3, the 5 new types accounted for 33–38% of lesions, with the
exception of North America and the older age group in Latin America
(17–18%). Notwithstanding this regional variance between the qHPV
vaccine types and the 5 new types, our study shows that the majority
(71–85%) of pre-cancerous cervical lesions (CIN2/3) in all the regions
studied are attributed to 9vHPV vaccine types.
Fig. 3. Percent of CIN1-3 attributed to HPV16/18, HPV 31/33/45/52/58, and HPV 35/39/51/56/59, by region, proportional method, in women ages 15–26 (panel A) and 24 to 45
(panel B). Only regions with 420 CIN2 or CIN3 lesions are shown.
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worldwide study of 8977 HPV-positive invasive cervical cancers, in
which there was also minimal regional variation [19]. Approxi-
mately 96%, 88%, 88%, 91%, 86% and 87% of the HPV-positive cer-
vical cancers in North America, Central South America, Europe,
Asia, Oceania, and Africa, respectively, were attributed to the high
risk 9v HPV vaccine types in that study. Our study results for the
attribution of cervical neoplasia to the 9vHPV vaccine types are
also consistent with 2 recent, large US studies of cervical neoplasia
[20,21]. One study was a population-based study of 5378 cervical
lesions conducted by the US Centers for Disease Control (CDC) in
5 catchment areas across the US among women aged 21–39
between 2008 and 2011. The other study was also population-
based and included 21,297 females aged 13–90 (mean ages at CIN2
and CIN3 diagnosis: 25 and 28, respectively) who had cervical
biopsies in New Mexico between 2006 and 2009. The attribution
of CIN2/3 to the high risk 9vHPV vaccine types was 75% (65.3% for
CIN2 and 86.2% for CIN3/AIS) in the CDC study, while in the New
Mexico study, the attribution of CIN2 and CIN3 to any 9vHPV
vaccine type was 65.9% and 82.3%, respectively [20,21]. Similarly,
we estimated that 76% of CIN2 lesions in women aged 15–26 are
attributed to the high risk 9vHPV vaccine types in North America
and 79% of CIN2/3 lesions in women aged 24–45 (in all regions
combined) are attributed to these types (Fig. 3). While we also
found that 97% of CIN3 lesions in women aged 15–26 in North
America are attributable to the high risk 9vHPV types, our sample
size was small (n¼35). Our estimate of 90% attribution of CIN3
lesions in all regions combined was within 4–6% of the CDC and
New Mexico studies for CIN3. The estimates of attribution of CIN2
and CIN3 to individual HPV types (e.g., 16/18) varied among these
3 studies, and they also varied by region in our study. The reason
for this variation is not clear. Importantly however, when attri-
bution of these lesions is assessed for the high risk 9vHPV vaccine
types combined, the differences among the studies and regions are
minimal.
Both our study and the New Mexico study [20] also evaluated
CIN1 attribution to the 9vHPV types. We found that among
women aged 15–26 years, approximately 44% of CIN1 was attri-
butable to the 9vHPV types in North America, and 46–50% of CIN1
in all regions combined in both age groups studied. In contrast, the
New Mexico study found that only 25% of CIN1 lesions were
attributed to the 9vHPV vaccine types overall, whereas in the age26 years old and under, the attribution of CIN1 to the 9vHPV
vaccine types was 30–35%.
Since diagnostic criteria and terminology varies in real world
practice, a strength of our study is the adjudicated consensus
diagnosis of CIN1-3 lesions by an expert pathology panel, rea-
sonably ruling out important potential misclassiﬁcation of our
lesion grades. Several large studies examining the percent agree-
ment between clinical center diagnoses and quality control (QC)
pathology diagnoses of cervical lesions have found poor agree-
ment, with the QC pathologists tending to give less severe diag-
noses [22,23].
For women aged 15–26 years, the mathematical approaches
(proportional, hierarchical and any) for assessing HPV type attri-
bution converged for the high-risk vaccine HPV types, regardless
of region. The proportional attribution methods showed that the 7
high-risk types contained in the 9vHPV vaccine contributed to
85%, 83% and 81% of CIN2/3 in North America, Latin America, and
Europe respectively. In women aged 24–45 years, these types
contributed to 71%, and 78% of CIN2/3 in Asia and Latin America,
respectively. Several studies have now shown good consistency
between the proportional and hierarchical attribution methods.
For example, in the CDC study described above the proportional
and hierarchical attribution methods yielded the same estimates
for the attribution of HPV16/18/31/33/45/52/58 to CIN2/3 (75%).
Under the proportional attribution method, the next most
common HPV types (other than the 9vHPV vaccine types) that
have been found in invasive cervical cancers at a proportion of
41% are: HPV35 (1.9%), HPV39 (1.6%), HPV51 (1.3%), HPV59 (1.1%),
and HPV56 (0.83%) [19]. In our study, these types collectively
contributed to 7%, 8% and 9% of CIN2/3 in North America, Latin
America, and Europe in women aged 15–26, respectively. In
women aged 24 to 45, these types contributed to 2%, and 11% of
CIN2/3 in Asia and Latin America. In 2012, the International
Agency for Research on Cancer concluded there was sufﬁcient
evidence of carcinogenicity to humans for the 7 high-risk HPV
types in the 9vHPV vaccine in addition to these 5 HPV types which
are not contained in the 9vHPV vaccine [24]. Less evidence was
available for HPV68, and 7 other phylogenetically related types
(HPV26/53/66/67/68/70/73) were considered possibly carcino-
genic [24]. These conclusions are supported by a recent Swedish
study that estimated the HPV type-speciﬁc risks of CIN2 and CIN3
using a randomized primary HPV screening trial with 14.6 years
follow-up. In that study, substantial differences were found in risk
X. Castellsagué et al. / Papillomavirus Research 2 (2016) 61–6968of CIN2 and CIN3 between different oncogenic HPV types – HPV16/
18/31/33/45/52/58 together contributed to 73.9% of CIN2/3 lesions
whereas HPV39/51/56/59/66/68 had risks of o10% [25]. Collec-
tively, these data inform HPV screening and vaccination strategies.
We found approximately 8% of CIN2/3 lesions to be negative to
the 14 tested HPV types across all regions and age groups with the
exception of Asia, where 21% (9 of 42) of the CIN2/3 lesions in
women aged 24–45 were negative to all of the 14 tested types. As
we cannot determine if our HPV negative lesions are attributed to
a non tested type, we included all lesions in our analyses, irre-
spective of their HPV status. When considering only HPV positive
lesions in women aged 15–26, the 7 high-risk types contained in
the 9vHPV vaccine contributed to 92%, 89.7% and 88.0% of CIN2/3
cases in North America, Latin America, and Europe, respectively. In
women aged 24–45 years, these types contributed to 90.9%, and
85.0% of CIN2/3 lesions in Asia and Latin America. These estimates
of 9vHPV attribution are closer to the de Sanjosé worldwide study
of 8977 HPV-positive invasive cervical cancers [19]. Also, the
proportion of our samples that were HPV positive is generally
consistent with that study, in which 8%, 18%, 13%, and 12% of
cancers were HPV negative in North America, Central South
America, Europe, and Asia, though the study tested for 30 HPV
types [19].
The study has some limitations. The clinical trial populations
are not entirely representative of the general population of women
aged 15–45 due to the per-protocol exclusion/inclusion criteria
used in the trials. Although this study provides data from 27
countries in 5 regions, some regions had small numbers of lesions
and not every country was represented for each region. Thus the
proportion and hierarchical attribution methods were only applied
to regions/countries where more than 20 lesions were detected.
Very few AIS lesions were detected across each region. Of the 24
total, 23 (95.8%) were attributed to the 9vHPV vaccine types.
According to recent literature from 5 countries with organized
cervical screening programs (the US and 4 Nordic countries), the
incidence of CIN2/3 is approximately 10 or more times higher than
the incidence of cervical cancer [26–29]. In all regions, CIN2/3
incidence is generally not well measured or consistently reported
and rates are likely to vary mainly due to differences in sexual
behaviors and screening and treatment programs. Nonetheless,
the CIN2/3 disease burden worldwide is clearly substantial, and
mostly attributable to the high risk 9vHPV vaccine types.5. Conclusions
In summary, the 5 new HPV types (31/33/45/51/58) in the
9vHPV vaccine accounted for approximately 25–30% of CIN1 in
Latin America and Europe, 14–18% of CIN1 in North America and
Asia, 33–38% of CIN2/3 in most regions, and 17–18% of CIN2/3 in
North America and Latin America (older age group). Irrespective of
region, if future 9vHPV vaccination programs are effectively
implemented in HPV naïve adolescents and young women, a
substantial number of cervical lesions could be prevented in set-
tings where HPV immunization programs have yet to be imple-
mented, as well as in settings currently implementing qHPV
(HPV6/11/16/18) and/or bivalent (HPV16/18) vaccines. 9vHPV
vaccination programs would also eliminate many invasive proce-
dures (colposcopy, biopsy, excisional surgery of the cervix) asso-
ciated with CIN treatment in countries with existing cervical
cancer screening programs, and a substantial number of cervical
cancers everywhere, including countries without screening pro-
grams. Broad immunization with the 9vHPV vaccine of adolescent
populations may thus necessitate evaluation of optimal screening
algorithms in HPV vaccinated women. Notwithstanding, and
regardless of screening practices and vaccine uptake, our datasuggest that the non-vaccine types 35/39/51/56/59 may still be
responsible for some CIN1, and to a lesser extent CIN2/3.Funding support
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